GLP-1 receptor antagonists can be classified as transitional longevity therapeutics, but more evidence is needed to assess their direct and indirect effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Chavda, V. P., Balar, P. C., Vaghela, D. A. & Dodiya, P. Maturitas https://doi.org/10.1016/j.maturitas.2024.108028 (2024).
Kreiner, F. F., von Scholten, B. J., Kurtzhals, P. & Gough, S. C. L. Aging Cell 22, e13818 (2023).
Krumholz, H. M. Circ. Cardiovasc. Qual. Outcomes 8, 457–459 (2015).
Fleming, T. R. Ann. Intern. Med. 153, 400–406 (2010).
Boekstein, N. et al. Nat. Biotechnol. 41, 1053–1055 (2023).
Gems, D., Okholm, S. & Lemoine, M. EMBO Rep. 25, 3748–3752 (2024).
Huang, J. et al. Cell Metab. 37, 2362–2380 (2025).
Marso, S. P. et al. N. Engl. J. Med. 375, 311–322 (2016).
Marso, S. P. et al. N. Engl. J. Med. 375, 1834–1844 (2016).
Lincoff, A. M. et al. N. Engl. J. Med. 389, 2221–2232 (2023).
Deanfield, J. et al. Lancet 404, 773–786 (2024).
Wilbon, S. S. & Kolonin, M. G. Cells 13, 65 (2023).
VanderWeele, T. J. & Ding, P. Ann. Intern. Med. 167, 268–274 (2017).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
A.Z. is an employee of and shareholder in Insilico Medicine, a generative AI-powered drug discovery and longevity company. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Marino, N., Fiore, M. & Zhavoronkov, A. GLP-1 receptor agonists should be rigorously tested as longevity therapeutics. Nat. Health (2026). https://doi.org/10.1038/s44360-026-00109-x
Published:
Version of record:
DOI: https://doi.org/10.1038/s44360-026-00109-x
